M 613
Pill imprint M 613 has been identified as Levetiracetam 250 mg.
Levetiracetam is used in the treatment of seizures; epilepsy; bipolar disorder; neuralgia; new daily persistent headache (and more), and belongs to the drug class pyrrolidine anticonvulsants. Risk cannot be ruled out during pregnancy.
Levetiracetam 250 mg is not subject to the Controlled Substances Act.
See also related documents.
Levetiracetam Images
- Imprint:
-
M 613
- Strength:
- 250 mg
- Color:
- White
- Size:
- 10.00 mm
- Shape:
- Round
- Availability:
- Prescription only
- Inactive Ingredients:
- silicon dioxide
croscarmellose sodium
hypromellose
magnesium stearate
microcrystalline cellulose
polydextrose
polyethylene glycol
povidone
sodium lauryl sulfate
titanium dioxide
triacetin
- Drug Class:
- Pyrrolidine anticonvulsants
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- N - Not a controlled drug
- Manufacturer:
- Mylan Pharmaceuticals Inc.
- National Drug Code (NDC):
- 00378-5613
| NDC Code | Manufacturer / Repackager |
|---|---|
| 51079-0820 | UDL Laboratories Inc |
| 35356-0429 | Lake Erie Medical and Surgical Supply (repackager) |
Note: Inactive ingredients may vary.
Advertisement
More Levetiracetam resources
- Levetiracetam (Wolters Kluwer)
- Levetiracetam Extended-Release Tablets (Wolters Kluwer)
- Levetiracetam Solution (Wolters Kluwer)
- Levetiracetam Tablets (Wolters Kluwer)
- levetiracetam (Cerner Multum)
- levetiracetam (Micromedex) - Includes Dosage Information
- levetiracetam Intravenous (Micromedex) - Includes Dosage Information
- Levetiracetam (AHFS DI)
- Keppra Injection (FDA)
- Levetiracetam (FDA)
- Levetiracetam Extended Release Tablets (FDA)
- Levetiracetam Injection (FDA)
- Levetiracetam Solution (FDA)
- Levetiracetam (Wolters Kluwer)
Search Again
